Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPCX
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
CTRA
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.69% |
| 2 | Industrials | 9.96% |
| 3 | Consumer Discretionary | 8.03% |
| 4 | Healthcare | 7.46% |
| 5 | Financials | 6.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2026
AutoZone
AZO
$48.3B
| $1.23M | ﹤0.01% |
386
-13,096
| -97% | -$43.5M |
|
2027
Nuvation Bio
NUVB
$2.43B
| $1.23M | ﹤0.01% |
217,124
+154,603
| +247% | +$756K |
|
2028
CALL
The GEO Group
GEO
$4.31B
| $1.23M | ﹤0.01% |
+41,600
| New | +$943K |
|
2029
PUT
Teladoc Health
TDOC
$1.16B
| $1.23M | ﹤0.01% |
144,600
| – | – |
|
2030
CALL
Novartis
NVS
$302B
| $1.22M | ﹤0.01% |
+7,800
| New | +$1.17M |
|
2031
Qfin Holdings
QFIN
$1.41B
| $1.22M | ﹤0.01% |
+77,296
| New | +$1.09M |
|
2032
CALL
Lennar Class A
LEN
$21B
| $1.22M | ﹤0.01% |
+13,500
| New | +$1.21M |
|
2033
Aflac
AFL
$58.2B
| $1.22M | ﹤0.01% |
10,392
-84,881
| -89% | -$9.77M |
|
2034
Trinity Capital Inc
TRIN
$1.74B
| $1.22M | ﹤0.01% |
68,011
-174,644
| -72% | -$2.88M |
|
2035
Navient
NAVI
$886M
| $1.22M | ﹤0.01% |
142,867
+118,185
| +479% | +$993K |
|
2036
OSI Systems
OSIS
$3.41B
| $1.22M | ﹤0.01% |
5,558
+1,493
| +37% | +$366K |
|
2037
CBIZ
CBZ
$2.97B
| $1.21M | ﹤0.01% |
37,832
-17,039
| -31% | -$530K |
|
2038
CALL
Synopsys
SNPS
$76.2B
| $1.2M | ﹤0.01% |
2,700
-17,800
| -87% | -$8.37M |
|
2039
CALL
Celestica
CLS
$37.4B
| $1.2M | ﹤0.01% |
+3,300
| New | +$1.24M |
|
2040
CALL
Clorox
CLX
$12.9B
| $1.2M | ﹤0.01% |
+12,600
| New | +$1.21M |
|
2041
PUT
XPeng
XPEV
$11.7B
| $1.2M | ﹤0.01% |
90,800
+2,600
| +3% | +$41.2K |
|
2042
Oaktree Specialty Lending
OCSL
$1.14B
| $1.2M | ﹤0.01% |
100,279
+17,537
| +21% | +$212K |
|
2043
Omega Healthcare
OHI
$14.1B
| $1.19M | ﹤0.01% |
+24,991
| New | +$1.16M |
|
2044
PUT
Best Buy
BBY
$18.1B
| $1.19M | ﹤0.01% |
15,700
-84,300
| -84% | -$5.6M |
|
2045
Blue Bird Corp
BLBD
$1.96B
| $1.19M | ﹤0.01% |
+15,078
| New | +$1.02M |
|
|
RTACU
2046
Renatus Tactical Acquisition Corp I Unit
RTACU
$188M
| $1.19M | ﹤0.01% |
108,411
-12,940
| -11% | -$138K |
|
2047
Federal Signal
FSS
$7.48B
| $1.19M | ﹤0.01% |
+9,245
| New | +$1.06M |
|
2048
Axalta
AXTA
$7.75B
| $1.19M | ﹤0.01% |
34,683
-1,758,012
| -98% | -$52.9M |
|
|
BULL
2049
CALL
Webull Corp
BULL
$4.67B
| $1.18M | ﹤0.01% |
181,700
+131,100
| +259% | +$849K |
|
2050
Golub Capital BDC
GBDC
$3.43B
| $1.18M | ﹤0.01% |
91,279
+47,799
| +110% | +$623K |
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $7.14B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 9.7% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.